BioSpace News Archive

AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced the National Comprehensive Cancer Network® (NCCN) has elevated FOTIVDA® (tivozanib) to Category 1 status as a subsequent therapy for RCC patients who have received two or more prior therapies in the latest Kidney Cancer Treatment Guidelines released on June 17, 2022.

Landos Biopharma, Inc., a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, announced that Gregory Oakes has been named President and Chief Executive Officer, and has been appointed to the Landos Board of Directors, effective immediately.

Summertime beachgoers are all too familiar with the painful reality of a jellyfish sting.

CareView Communications, Inc. (“CareView” or the “Company”) (OTCQB: CRVW), an information technology provider to the healthcare industry, has been selected to exhibit the CareView Patient Safety System®, including its patented, predictive Virtual Bed Rails® and Virtual Chair Rails® technology, at the Vizient Innovative Technology Exchange.

9 Meters Biopharma, Inc. today announced completion of a pre-specified interim analysis for the Phase 3 study of larazotide, referred to as CedLara® (Celiac disease Larazotide), for patients with celiac disease who continue to experience gastrointestinal symptoms while adhering to a gluten-free diet.

Recognizing the breadth of application of its patented extracorporeal treatment approach, Halberd Corporation (OTC Pink: HALB) announced the creation of a subgroup of researchers to focus on cancer treatment.

Agilent Technologies Inc. (NYSE: A) today announced that the company’s customer demonstration laboratory in Waldbronn, Germany has received the highest level of Green Lab Certification , the gold standard in laboratory sustainability best practices.

Novocure Enrolls First Patient in KEYNOTE-B36, a Pilot Study of Tumor Treating Fields Together with KEYTRUDA ® for Patients with First-Line Stage III Non-Small Cell Lung Cancer.

Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on advancing therapeutics for rare and degenerative diseases, today announced new preclinical data demonstrating the efficacy of the company’s 3CLpro inhibitor, COR803, for treatment of coronavirus infections, including COVID-19 disease, caused by SARS-CoV-2 infection.

Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced the promotion of Tanya Hayden to Chief Operating Officer (COO).